Dena Grayson | |
---|---|
![]() | |
Personal details | |
Born | Dena Minning January 5, 1971 Melbourne, Florida, U.S. |
Political party | Democratic |
Spouse | Alan Grayson (m. 2016) |
Education | University of Florida (BSc) Washington University (MSc, MD, PhD) |
Website | Campaign website |
Dena Minning Grayson (born Dena Minning, January 5, 1971) is an American medical doctor and researcher. In 2016, she ran unsuccessfully for the Democratic nomination for the United States House of Representatives for Florida's 9th congressional district. [1]
Dena Minning Grayson was born on January 5, 1971, in Melbourne, Florida. Grayson graduated from Melbourne High School in 1988 [2] where she was a member of the varsity soccer team that captured the Florida High School State Championship in 1987. [3] She earned her Bachelor of Science degree [4] from the University of Florida in 1992. After graduating from college, Grayson enrolled in the Medical Scientist Training Program at Washington University School of Medicine, [5] where she earned an MD and a PhD in biochemistry and molecular cell biology. [4] [6] In 1999, The New York Times , [7] Science Daily and the Duke Chronicle [8] covered research on Ascaris hemoglobin [9] that Grayson had published in Nature , and stated, "The discovery may yield new therapies for diseases such as cancer, in which starving tumors of oxygen is a major therapeutic focus." [10] Grayson completed her internship in internal medicine at the University of California, San Francisco. [11] [12]
Grayson has a medical degree. In the early 2000s, she shifted her focus to medical research as a way of treating multiple patients by finding cures. [13] She worked as a biotechnology consultant at MEDACorp from 2002-2003. [14] From 2003 to 2008, Grayson served as an Associate Director of Licensing and Director of Medical Sciences at Amgen, and worked on developing treatments for cancers, asthma, anemia, hypercholesterolemia, heart failure, and pain. While at Amgen, she was selected as a Henry Crown Fellow at the Aspen Institute in 2006. [15] Grayson then served as Vice President of Translational Sciences at 3-V Biosciences from 2008 to 2010, [14] where she oversaw the development of broad-spectrum antiviral drugs active against deadly viruses. She served as the Vice President of Translational Sciences for AlloCure from 2011 to 2014, where she led research on a mesenchymal stem cell therapy for acute kidney injury. In 2010, Grayson founded MedExpert Consulting, a biotechnology consulting company, where she helped research and develop BCX4430, a broad-spectrum antiviral drug that is active against Ebola, Marburg, Yellow Fever, Zika, and other deadly viral diseases. [16] [17] [18] [19] Grayson briefly lobbied for BioCryst Pharmaceuticals for 3 months in 2013 and for 1 month in 2014 to fund research of a treatment for Ebola and other deadly viruses. [18] [20] In 2014, she was co-author of an article published in Nature on the efficacy of BCX4430 against Marburg virus [16] and of a paper on the activity of BCX4430 against Yellow Fever. [17]
In 2016, she ran unsuccessfully for the Democratic nomination for the United States House of Representatives for Florida's 9th congressional district. [1] Since 2016, Grayson is a regular political commentator on Twitter, and asked onto media such as Fox News to speak on issues such as the Democrats proposal to reform elections. [21] Grayson attended the Michael Cohen hearing in February 2019. [22]
Since 2016, she has been married to former Congressman Alan Grayson. [23]
The Hot Zone: A Terrifying True Story is a best-selling 1994 nonfiction thriller by Richard Preston about the origins and incidents involving viral hemorrhagic fevers, particularly ebolaviruses and marburgviruses. The basis of the book was Preston's 1992 New Yorker article "Crisis in the Hot Zone".
Sylvia Mary Burwell is an American government and non-profit executive who has been the 15th president of American University since June 1, 2017. Burwell is the first woman to serve as the university's president. Burwell earlier served as the 22nd United States Secretary of Health and Human Services. President Barack Obama nominated Burwell on April 11, 2014. Burwell's nomination was confirmed by the Senate on June 5, 2014, by a vote of 78–17. She served as Secretary until the end of the Obama administration. Previously, she had been the Director of the White House Office of Management and Budget from 2013 to 2014.
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Zika virus is a member of the virus family Flaviviridae. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Ziika Forest of Uganda, where the virus was first isolated in 1947. Zika virus shares a genus with the dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Since the 1950s, it has been known to occur within a narrow equatorial belt from Africa to Asia. From 2007 to 2016, the virus spread eastward, across the Pacific Ocean to the Americas, leading to the 2015–2016 Zika virus epidemic.
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.
Christopher Mores is an American (US) arbovirologist, trained in infectious disease epidemiology. He is a professor in the Department of Global Health at the Milken Institute School of Public Health, the program director for the Global Health Epidemiology and Disease Control MPH program, and is director of a high-containment research laboratory at the George Washington University in Washington, DC.
Galidesivir is an antiviral drug, an adenosine analog. It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.
There is a cure for the Ebola virus disease that is currently approved for market the US government has inventory in the Strategic National Stockpile. For past and current Ebola epidemics, treatment has been primarily supportive in nature.
An epidemic of Zika fever, caused by Zika virus, began in Brazil and affected other countries in the Americas from April 2015 to November 2016. The World Health Organization (WHO) declared the end of the epidemic in November 2016, but noted that the virus still represents "a highly significant and long term problem". It is estimated that 1.5 million people were infected by Zika virus in Brazil, with over 3,500 cases of infant microcephaly reported between October 2015 and January 2016. The epidemic also affected other parts of South and North America, as well as several islands in the Pacific.
This article primarily covers the chronology of the 2015–16 Zika virus epidemic. Flag icons denote the first announcements of confirmed cases by the respective nation-states, their first deaths, and relevant sessions and announcements of the World Health Organization (WHO), and the U.S. Centers for Disease Control (CDC), as well as relevant virological, epidemiological, and entomological studies.
Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
MK-608 is an antiviral drug, an adenosine analog. It was originally developed by Merck & Co. as a treatment for hepatitis C, but despite promising results in animal studies, it was ultimately unsuccessful in clinical trials. Subsequently it has been widely used in antiviral research and has shown activity against a range of viruses, including Dengue fever, tick-borne encephalitis virus, poliovirus, and most recently Zika virus, in both in vitro and animal models. Since it has already failed in human clinical trials previously, it is unlikely MK-608 itself will be developed as an antiviral medication, but the continuing lack of treatment options for these emerging viral diseases means that much research continues using MK-608 and related antiviral drugs.
NITD008 is an antiviral drug classified as an adenosine analog. It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus. However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.
John Payne Woodall (1935–2016), known as Jack Woodall, was an American-British entomologist and virologist who made significant contributions to the study of arboviruses in South America, the Caribbean and Africa. He did research on the causative agents of dengue fever, Crimean–Congo hemorrhagic fever, o'nyong'nyong fever, yellow fever, Zika fever, and others.
Tara C. Smith is an American epidemiologist and science communicator. She is a professor at the Kent State University College of Public Health who studies zoonotic infections. Smith was the first to identify strains of methicillin-resistant Staphylococcus aureus associated with livestock in the United States.
Daniel R. Lucey is an American physician, researcher, clinical professor of medicine of infectious diseases at Geisel School of Medicine at Dartmouth, and a research associate in anthropology at the Smithsonian National Museum of Natural History, where he has co-organised an exhibition on eight viral outbreaks.
Neil Morris Ferguson is a British epidemiologist and professor of mathematical biology, who specialises in the patterns of spread of infectious disease in humans and animals. He is the director of the Jameel Institute, and of the MRC Centre for Global Infectious Disease Analysis, and head of the Department of Infectious Disease Epidemiology in the School of Public Health and Vice-Dean for Academic Development in the Faculty of Medicine, all at Imperial College London.
Trudie Lang is a Professor of Global Health Research at the University of Oxford. She specialises in clinical trials research capacity building in low-resource setting, and helped to organise the trial for the drug brincidofovir during the 2014 Ebola virus outbreak.
Natalie E. Dean is an American biostatistician specializing in infectious disease epidemiology. Dean is currently an assistant professor of Biostatistics at the University of Florida. Her research involves epidemiological modeling of outbreaks, including Ebola, Zika and COVID-19.
{{cite web}}
: |first=
has generic name (help)